Affiliation:
1. Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences
2. Department of Medical Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences
Abstract
Abstract
Background
Gastric cancer (GC) is the third leading cause of cancer-related death in the world and is often diagnosed at an advanced stage due to the lack of appropriate biomarkers. Long non-coding RNAs (lncRNAs) are considered promising biomarkers in various cancers such as GC. LincRNA-p21 is located upstream of the p21 (Cdkn1) tumor suppressor gene and regulates its expression. Despite reports of lincRNA-p21 deregulation in some cancers, its role in GC has not been well clarified.
Materials &Methods:
In this case-control study, total RNA was extracted from 33 matched pairs of tumor and non-tumor gastric samples and also gastric cancer cell lines (AGS and MKN45). Following cDNA synthesis, real-time PCR was performed. Data analysis was conducted by the GenEX5 and Statistical Program for Social Sciences (SPSS) software programs.
Results
Our results revealed a significant decrease in the expression of LncRNA-p21 in tumor samples compared to non-tumor samples (P = 0.009). The ability of LncRNA-p21expression level to discriminate between tumor and non-tumor samples was confirmed by ROC analysis. Additionally, lincRNA-p21 was found to be decreased in different grades of cancer.
Conclusions
The downregulation of lincRNA-p21 may leading to the loss of cell cycle control and increased tumorigenicity. Moreover, the observation that decreased expression of lincRNA-p21 occurs in different grades of malignancy highlights the potential of lincRNA-p21 as a valuable biomarker for the early diagnosis and prognosis of gastric cancer.
Publisher
Research Square Platform LLC